Global Chronic Myeloid Leukemia (CML) Market Report 2017: Focus on Forecasts, Treatment, Epidemiology, Marketed Drugs & Pipeline

Chronic myeloid leukemia (CML), also known as chronic myelogenous leukemia, is a myeloproliferative disorder characterized by a single cytogenetic hallmark: the chromosomal translocation t(9;22)(q34;q11), known as the Philadelphia (Ph) chromosome. In a small minority of patients who exhibit the characteristics of CML, the Ph chromosome cannot be detected - this is referred to as Ph-negative CML, or atypical CML.

Chronic myeloid leukemia (CML), also known as chronic myelogenous leukemia, is a myeloproliferative disorder characterized by a single cytogenetic hallmark: the chromosomal translocation t(9;22)(q34;q11), known as the Philadelphia (Ph) chromosome. In a small minority of patients who exhibit the characteristics of CML, the Ph chromosome cannot be detected - this is referred to as Ph-negative CML, or atypical CML.

Market Snapshot

Key Topics Covered:

Forecast: Chronic Myeloid Leukemia

Treatment: Chronic Myeloid Leukemia

Epidemiology: Chronic Myeloid Leukemia In The Us, Japan, And 5EU

Marketed Drugs: Chronic Myeloid Leukemia

Pipeline: Chronic Myeloid Leukemia

For more information about this report visit https://www.researchandmarkets.com/research/k7kr9g/global_chronic?w=5

Media Contact:

Laura Wood, Senior Manager
press@researchandmarkets.com  

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716